Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | RBBP9 | O75884 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.35 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653141 | 0.81 | ALDH1A1 (0.61) | ALDH1A1RBBP9KMT2AL3MBTL1CYP1A2 | |
| SCHEMBL1009292 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL28652061 | 0.72 | ALDH1A1 (0.59) | ALDH1A1RBBP9KMT2AL3MBTL1CYP1A2 | |
| SCHEMBL4968793 | 0.70 | CLK1 (0.37) | ALDH1A1CLK1DYRK1ADYRK1BTRPM8 | |
| SCHEMBL2305787 | 0.70 | HSD17B10 (0.39) | ALDH1A1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL29529044 | 0.70 | ALDH1A1 (0.47) | ALDH1A1RBBP9L3MBTL1CYP1A2CYP2D6 | |
| SCHEMBL247631 | 0.70 | — | — | |
| SCHEMBL2308777 | 0.69 | TRPM8 (0.38) | ALDH1A1KMT2AL3MBTL1MAPTNPC1 | |
| SCHEMBL175249 | 0.69 | ALDH1A1 (0.67) | ALDH1A1RBBP9KMT2ACYP1A2CYP2D6 | |
| SCHEMBL28027939 | 0.69 | ALDH1A1 (0.67) | ALDH1A1RBBP9KMT2AL3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144767-A1 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144767-A1 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144767-A1 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-05-11 | — | — | US | disclosed |
| US-20210371460-A1 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-12-02 | — | — | US | disclosed |
| US-20200317730-A1 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317730-A1 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-10-08 | — | — | US | disclosed |
| US-10751273-B2 | Compounds for the treatment of pathologies associated with aging and degenerative disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190210969-A1 | INTRAESOPHAGEAL ADMINISTRATION OF TARGETED NITROXIDE AGENTS FOR PROTECTION AGAINST IONIZING IRRADIATION-INDUCED ESOPHAGITIS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-07-11 | — | — | US | disclosed |
| US-20180298054-A1 | TARGETED NITROXIDE AGENTS | University of Pittsburgh - of the Commonwealth Sys tem of Higher Education (US) | 2018-10-18 | — | — | US | disclosed |
| US-9890192-B2 | Targeted nitroxide agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2018-02-13 | — | — | US | disclosed |
| US-20110172214-A1 | USE OF TARGETED NITROXIDE AGENTS IN PREVENTING, MITIGATING AND TREATING RADIATION INJURY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2011-07-14 | — | — | US | disclosed |
| WO-2010141824-A2 | USE OF TARGETED NITROXIDE AGENTS IN BONE HEALING | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010043893-A1 | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | WO | disclosed |
| US-20100035869-A1 | TARGETED NITROXIDE AGENTS | PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, UNIVERSITY OF | 2010-02-11 | — | — | US | disclosed |
| US-20100035869-A1 | TARGETED NITROXIDE AGENTS | PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, UNIVERSITY OF | 2010-02-11 | — | — | US | disclosed |
| US-20100035869-A1 | TARGETED NITROXIDE AGENTS | PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, UNIVERSITY OF | 2010-02-11 | — | — | US | disclosed |
| WO-2010009389-A1 | USE OF TARGETED NITROXIDE AGENTS IN PREVENTING, MITIGATING AND TREATING RADIATION INJURY | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090042808-A1 | USE OF MITOCHONDRIA-TARGETED ELECTRON SCAVENGERS AS ANTI-INFLAMMATORY AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-12 | — | — | US | disclosed |
| US-20090042808-A1 | USE OF MITOCHONDRIA-TARGETED ELECTRON SCAVENGERS AS ANTI-INFLAMMATORY AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-12 | — | — | US | disclosed |
| US-20080312206-A1 | Chemical Compounds-149 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312206-A1 | Chemical Compounds-149 | CSF3R, CSF1R, FLT3 | ALDH1A1 1081/4885RBBP9 1900/4885KMT2A 1047/4885 |
| US-20110172214-A1 | USE OF TARGETED NITROXIDE AGENTS IN PREVENTING, MITIGATING AND TREATING RADIATION INJURY | TXNRD2, TXN2, HSPE1 | ALDH1A1 1685/4885RBBP9 449/4885KMT2A 3662/4885 |
| US-20190210969-A1 | INTRAESOPHAGEAL ADMINISTRATION OF TARGETED NITROXIDE AGENTS FOR PROTECTION AGAINST IONIZING IRRADIATION-INDUCED ESOPHAGITIS | HSPE1, HSPA9, HSPD1 | ALDH1A1 1888/4885RBBP9 687/4885KMT2A 4317/4885 |
| US-20090042808-A1 | USE OF MITOCHONDRIA-TARGETED ELECTRON SCAVENGERS AS ANTI-INFLAMMATORY AGENTS | HAGH, COX5B, HSPE1 | ALDH1A1 2684/4885RBBP9 2951/4885KMT2A 4560/4885 |
| US-20180298054-A1 | TARGETED NITROXIDE AGENTS | TXNRD2, TXN2, HSPE1 | ALDH1A1 2264/4885RBBP9 598/4885KMT2A 3194/4885 |
| US-20200317730-A1 | TARGETED NITROXIDE AGENTS | TXNRD2, TXN2, HSPE1 | ALDH1A1 2264/4885RBBP9 598/4885KMT2A 3194/4885 |
| US-20100035869-A1 | TARGETED NITROXIDE AGENTS | TXNRD2, TXN2, HSPE1 | ALDH1A1 2264/4885RBBP9 598/4885KMT2A 3194/4885 |
| US-10751273-B2 | Compounds for the treatment of pathologies associated with aging and degenerative disorders | GLA, AGER, SIRT1 | ALDH1A1 315/4885RBBP9 2275/4885KMT2A 3286/4885 |
| US-20230144767-A1 | TARGETED NITROXIDE AGENTS | TXNRD2, TXN2, HSPE1 | ALDH1A1 2264/4885RBBP9 598/4885KMT2A 3194/4885 |
| US-20210371460-A1 | TARGETED NITROXIDE AGENTS | TXNRD2, TXN2, HSPE1 | ALDH1A1 2264/4885RBBP9 598/4885KMT2A 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.